191st ENMC International Workshop: Recent advances in oculopharyngeal muscular dystrophy research: From bench to bedside 8-10 June 2012, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 23, Issue 6, 2013, Pages 516-523

  Raz, Vered ^a   Butler Browne, Gillian ^b   van Engelen, Baziel ^c   Brais, Bernard ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Institut de Myologie   (France)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

ARTICLE; AUTOGRAFT; AWARENESS; CLINICAL FEATURE; DISEASE SEVERITY; GENE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HOMEOSTASIS; HUMAN; MEDICAL RESEARCH; MOLECULAR GENETICS; MYOBLAST; NETHERLANDS; NOMENCLATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PABPN1 GENE; PATHOGENESIS; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; QUESTIONNAIRE; UBIQUITINATION; WORKSHOP;

AGE OF ONSET; AGING; ANIMALS; DISEASE MODELS, ANIMAL; EDUCATION; HUMANS; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; MUTATION; NETHERLANDS;

EID: 84878635907     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.03.001     Document Type: Article

References (32)

1. Albrecht A., Mundlos S. The other trinucleotide repeat: polyalanine expansion disorders. Curr Opin Genet Dev 2005, 15:285-293.
2. Brais B., Bouchard J.P., Xie Y.G., et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998, 18:164-167.
3. Blumen S.C., Bouchard J.P., Brais B., et al. Cognitive impairment and reduced life span of oculopharyngeal muscular dystrophy homozygotes. Neurology 2009, 73:596-601.
4. Dubbioso R., Moretta P., Manganelli F., et al. Executive functions are impaired in heterozygote patients with oculopharyngeal muscular dystrophy. J Neurol 2012, 259:833-837.
5. Mizoi Y., Yamamoto T., Minami N., et al. Oculopharyngeal muscular dystrophy associated with dementia. Int Med 2011, 50:2409-2412.
6. Mathieu J., Lapointe G., Brassard A., et al. A pilot study on upper esophageal sphincter dilatation for the treatment of dysphagia in patients with oculopharyngeal muscular dystrophy. Neuromuscul Disord NMD 1997, 7(Suppl. 1):S100-S104.
7. Brigand C., Ferraro P., Martin J., Duranceau A. Risk factors in patients undergoing cricopharyngeal myotomy. Br J Surg 2007, 94:978-983.
8. Taillefer R., Duranceau A.C. Manometric and radionuclide assessment of pharyngeal emptying before and after cricopharyngeal myotomy in patients with oculopharyngeal muscular dystrophy. J Thorac Cardiovasc Surg 1988, 95:868-875.
9. Fischmann A., Hafner P., Fasler S., et al. Quantitative MRI can detect subclinical disease progression in muscular dystrophy. J Neurol 2012, 259:1648-1654.
10. Périé S., Mamchaoui K., Mouly V., et al. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: therapeutic perspectives of autologous myoblast transplantation. Neuromuscul Disord NMD 2006, 16:770-781.
11. Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy. Curr Neurol Neurosci Rep 2009, 9:76-82.
12. Messaed C., Dion P.A., Abu-Baker A., et al. Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy. Neurobiol Dis 2007, 26:546-557.
13. Raz V., Abraham T., van Zwet E.W., Dirks R.W., Tanke H.J., van der Maarel S.M. Reversible aggregation of PABPN1 pre-inclusion structures. Nucleus 2011, 2:208-218.
14. Raz V., Routledge S., Venema A., et al. Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein. Am J Pathol 2011, 179:1988-2000.
15. de Klerk E., Venema A., Anvar S.Y., et al. Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res 2012, 40:9089-9101.
16. Apponi L.H., Leung S.W., Williams K.R., Valentini S.R., Corbett A.H., Pavlath G.K. Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis. Hum Mol Genet 2010, 19:1058-1065.
17. Calado A., Tome F.M., Brais B., et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000, 9:2321-2328.
18. Jenal M., Elkon R., Loayza-Puch F., et al. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 2012, 149:538-553.
19. Anvar S.Y., t Hoen P.A., Venema A., et al. Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients. Skelet Muscle 2011, 1:15.
20. Anvar S.Y., Tucker A., Vinciotti V., et al. Interspecies translation of disease networks increases robustness and predictive accuracy. PLoS Computat Biol 2011, 7:e1002258.
21. Chartier A., Benoit B., Simonelig M. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J 2006, 25:2253-2262.
22. Barbezier N., Chartier A., Bidet Y., et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med 2011, 3:35-49.
23. Chartier A., Raz V., Sterrenburg E., Verrips C.T., van der Maarel S.M., Simonelig M. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum Mol Genet 2009, 18:1849-1859.
24. Davies J.E., Wang L., Garcia-Oroz L., et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 2005, 11:672-677.
25. Davies J.E., Berger Z., Rubinsztein D.C. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder. Int J Biochem Cell Biol 2006, 38:1457-1462.
26. Green D.R., Galluzzi L., Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011, 333:1109-1112.
27. Trollet C., Anvar S.Y., Venema A., et al. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum Mol Genet 2010, 19:2191-2207.
28. Hino H., Araki K., Uyama E., et al. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Hum Mol Genet 2004, 13:181-190.
29. Mankodi A., Wheeler T.M., Shetty R., Salceies K.M., Becher M.W., Thornton C.A. Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy. Neurobiol Dis 2012, 45:539-546.
30. Catoire H., Pasco M.Y., Abu-Baker A., et al. Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum Mol Genet 2008, 17:2108-2117.
31. Wang Q., Bag J. Ectopic expression of a polyalanine expansion mutant of poly(A)-binding protein N1 in muscle cells in culture inhibits myogenesis. Biochem Biophys Res Commun 2006, 340:815-822.
32. Verheesen P., de Kluijver A., van Koningsbruggen S., et al. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear poly(A)-binding protein with a single-domain intracellular antibody. Hum Mol Genet 2006, 15:105-111.